ECSP22073580A - Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano - Google Patents
Compuesto de oxazolidinona y métodos de uso de este como agente antibacterianoInfo
- Publication number
- ECSP22073580A ECSP22073580A ECSENADI202273580A ECDI202273580A ECSP22073580A EC SP22073580 A ECSP22073580 A EC SP22073580A EC SENADI202273580 A ECSENADI202273580 A EC SENADI202273580A EC DI202273580 A ECDI202273580 A EC DI202273580A EC SP22073580 A ECSP22073580 A EC SP22073580A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- formula
- methods
- antibacterial agent
- oxazolidinone compound
- Prior art date
Links
- -1 OXAZOLIDINONE COMPOUND Chemical class 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al compuesto de oxazolidinona de la Fórmula I: (I) y sales farmacéuticamente aceptables del mismo. La presente invención también se refiere a composiciones que contienen el compuesto de la Fórmula I. La invención también proporciona métodos para inhibir el crecimiento de células micobacterianas así como un método para tratar infecciones por micobacterias por Mycobacterium tuberculosis al administrar una cantidad terapéuticamente eficaz de la Fórmula I y/o una sal farmacéuticamente aceptable del mismo, o una composición que comprende tal compuesto y/o sal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/080359 WO2021184339A1 (en) | 2020-03-20 | 2020-03-20 | Oxazolidinone compound and methods of use thereof as an antibacterial agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22073580A true ECSP22073580A (es) | 2022-11-30 |
Family
ID=75478174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202273580A ECSP22073580A (es) | 2020-03-20 | 2022-09-19 | Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240208958A1 (es) |
| EP (1) | EP4121058A1 (es) |
| JP (1) | JP7241984B2 (es) |
| KR (1) | KR20220156577A (es) |
| CN (1) | CN115605208A (es) |
| AR (1) | AR121598A1 (es) |
| AU (1) | AU2021239937B2 (es) |
| BR (1) | BR112022018674A2 (es) |
| CA (1) | CA3172304A1 (es) |
| CL (1) | CL2022002511A1 (es) |
| CO (1) | CO2022013595A2 (es) |
| CR (1) | CR20220472A (es) |
| EC (1) | ECSP22073580A (es) |
| GE (1) | GEP20247641B (es) |
| IL (1) | IL296401A (es) |
| MX (1) | MX2022011431A (es) |
| PE (1) | PE20230002A1 (es) |
| TW (1) | TWI799814B (es) |
| WO (2) | WO2021184339A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022025918A2 (pt) | 2020-06-18 | 2023-03-14 | Akagera Medicines Inc | Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos |
| AU2022399569A1 (en) * | 2021-11-30 | 2024-06-06 | Mannkind Corporation | Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers |
| EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
| WO2024035618A1 (en) * | 2022-08-10 | 2024-02-15 | Merck Sharp & Dohme Llc | Processes for preparing oxazolidinone compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK283420B6 (sk) * | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
| PL356478A1 (en) * | 1999-12-21 | 2004-06-28 | Pharmacia & Upjohn Company | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
| PE20020044A1 (es) | 2000-06-16 | 2002-01-30 | Upjohn Co | Tiazina oxazolidinona |
| AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| WO2002032857A1 (en) * | 2000-10-17 | 2002-04-25 | Pharmacia & Upjohn Company | Methods of producing oxazolidinone compounds |
| MXPA03006958A (es) * | 2001-02-05 | 2003-11-18 | Upjohn Co | Composicion para administracion rectal de farmaco antibacterial de oxazolidinona. |
| GB0108764D0 (en) * | 2001-04-07 | 2001-05-30 | Astrazeneca Ab | Chemical compounds |
| MXPA04008173A (es) * | 2002-02-22 | 2004-11-26 | Pharmacia Corp | Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio. |
| WO2005113520A1 (en) * | 2004-05-20 | 2005-12-01 | Pharmacia & Upjohn Company Llc | Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents |
| EP1778653A1 (en) | 2004-07-28 | 2007-05-02 | Rib-X Pharmaceuticals, Inc. | Biaryl heterocyclic compounds and methods of making and using the same |
| WO2006059221A2 (en) * | 2004-12-03 | 2006-06-08 | Pharmacia & Upjohn Company Llc | Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents |
| WO2006079896A2 (en) * | 2005-01-27 | 2006-08-03 | Pharmacia & Upjohn Company Llc | Stable polyol formulations of oxazolidinone antibacterial agents |
| WO2009157423A1 (ja) | 2008-06-24 | 2009-12-30 | 財団法人乙卯研究所 | 縮合環を有するオキサゾリジノン誘導体 |
| CN102143748A (zh) * | 2008-09-03 | 2011-08-03 | 辉瑞大药厂 | 用于肺结核的联合疗法 |
| EP2311457A1 (en) * | 2009-10-19 | 2011-04-20 | Forschungszentrum Borstel | Pharmaceutical compositions for treating infections with drug resistant mycobacteria |
| EA037643B1 (ru) | 2015-07-17 | 2021-04-26 | Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. | Замещенные фенилоксазолидиноны для антимикробной терапии |
| WO2017066964A1 (en) * | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
| WO2018170664A1 (en) * | 2017-03-20 | 2018-09-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
-
2020
- 2020-03-20 WO PCT/CN2020/080359 patent/WO2021184339A1/en active Application Filing
-
2021
- 2021-03-17 TW TW110109522A patent/TWI799814B/zh active
- 2021-03-17 MX MX2022011431A patent/MX2022011431A/es unknown
- 2021-03-17 AR ARP210100669A patent/AR121598A1/es unknown
- 2021-03-17 JP JP2022555750A patent/JP7241984B2/ja active Active
- 2021-03-17 BR BR112022018674A patent/BR112022018674A2/pt not_active Application Discontinuation
- 2021-03-17 KR KR1020227035951A patent/KR20220156577A/ko not_active Application Discontinuation
- 2021-03-17 AU AU2021239937A patent/AU2021239937B2/en active Active
- 2021-03-17 CA CA3172304A patent/CA3172304A1/en active Pending
- 2021-03-17 CN CN202180036146.XA patent/CN115605208A/zh active Pending
- 2021-03-17 WO PCT/US2021/022652 patent/WO2021188606A1/en active Application Filing
- 2021-03-17 EP EP21718283.1A patent/EP4121058A1/en active Pending
- 2021-03-17 CR CR20220472A patent/CR20220472A/es unknown
- 2021-03-17 GE GEAP202116059A patent/GEP20247641B/en unknown
- 2021-03-17 IL IL296401A patent/IL296401A/en unknown
- 2021-03-17 PE PE2022002043A patent/PE20230002A1/es unknown
- 2021-03-20 US US17/909,834 patent/US20240208958A1/en active Pending
-
2022
- 2022-09-14 CL CL2022002511A patent/CL2022002511A1/es unknown
- 2022-09-19 EC ECSENADI202273580A patent/ECSP22073580A/es unknown
- 2022-09-21 CO CONC2022/0013595A patent/CO2022013595A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220156577A (ko) | 2022-11-25 |
| WO2021184339A1 (en) | 2021-09-23 |
| BR112022018674A2 (pt) | 2022-11-01 |
| PE20230002A1 (es) | 2023-01-05 |
| EP4121058A1 (en) | 2023-01-25 |
| MX2022011431A (es) | 2022-10-03 |
| JP7241984B2 (ja) | 2023-03-17 |
| WO2021188606A1 (en) | 2021-09-23 |
| AR121598A1 (es) | 2022-06-22 |
| CR20220472A (es) | 2022-11-14 |
| CA3172304A1 (en) | 2021-09-23 |
| GEP20247641B (en) | 2024-07-10 |
| AU2021239937B2 (en) | 2023-10-26 |
| JP2023507683A (ja) | 2023-02-24 |
| TWI799814B (zh) | 2023-04-21 |
| CO2022013595A2 (es) | 2023-02-16 |
| TW202200573A (zh) | 2022-01-01 |
| US20240208958A1 (en) | 2024-06-27 |
| IL296401A (en) | 2022-11-01 |
| AU2021239937A1 (en) | 2022-10-06 |
| CL2022002511A1 (es) | 2023-03-24 |
| CN115605208A (zh) | 2023-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22073580A (es) | Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano | |
| ECSP21080528A (es) | Compuestos antivirales que contienen nitrilo | |
| AR112271A1 (es) | Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
| NZ595448A (en) | Hydroxythienoquinolones and related compounds as anti-infective agents | |
| BR112019024549A2 (pt) | compostos derivados de glicopeptídeo e usos dos mesmos | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| BR112017015744A2 (pt) | composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas | |
| PE20240769A1 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| ECSP21093897A (es) | Compuestos y métodos de uso de los mismos como agentes antibacterianos | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| BR112017008101A2 (pt) | composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto. | |
| BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto | |
| UY39780A (es) | Composición fungicida que contiene compuestos de oxadiazol | |
| AR072389A1 (es) | Compuesto de 3-cianopirrolidinil-fenil-oxazolidinona, procedimiento para prepararlo, composicion farmaceutica que la comprende y sus usos | |
| AR121582A1 (es) | Composiciones antivirales y métodos de uso | |
| CO2023001204A2 (es) | Composición oral sólida que comprende compuesto de carbamato y método de preparación para la misma | |
| CL2022001935A1 (es) | Compuestos antivirales que contienen nitrilo | |
| AR127582A1 (es) | Métodos para el tratamiento del cáncer | |
| AR128100A1 (es) | Compuestos para el tratamiento de la pérdida del cabello | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| AR110330A1 (es) | Uso de derivados de bencimidazol para escape ácido nocturno |